House of Commons - Science and Technology Committee: Clinical Trials - HC 104
Author | : Great Britain: Parliament: House of Commons: Science and Technology Committee |
Publisher | : The Stationery Office |
Total Pages | : 210 |
Release | : 2013-09-17 |
ISBN-10 | : 0215062329 |
ISBN-13 | : 9780215062321 |
Rating | : 4/5 (321 Downloads) |
Download or read book House of Commons - Science and Technology Committee: Clinical Trials - HC 104 written by Great Britain: Parliament: House of Commons: Science and Technology Committee and published by The Stationery Office. This book was released on 2013-09-17 with total page 210 pages. Available in PDF, EPUB and Kindle. Book excerpt: Many of the trials taking place today are unregistered and unpublished, meaning that the information that they generate remains invisible to both the scientific community and the public. This undermines public trust, slowing the pace of medical advancement and potentially putting patients at risk. All trials conducted on NHS treatments-and all other trials receiving public funding-should be prospectively registered and their results published in a scientific journal. While the focus should be on implementing this change for future trials, the Government must also do what it can to ensure that historic trials are registered and published, particularly where they have been publically funded. The Government should also take steps to facilitate greater sharing of the raw data generated during a trial in a responsible and controlled way, with the knowledge and consent of patients. The report also draws attention to the recent fall in the number of trials taking place in the UK. It finds that the need for multiple governance approvals from participating NHS organisations remained the biggest barrier to setting up a UK trial, but that lack of public awareness was also a key issue. Recruiting participants can also be a challenge. The report calls on the Government to take its recommendations into account in ongoing discussions regarding the revision of European clinical trials legislation and in its response to the European Medicines Agency's consultation on the release of clinical trial data, which closes at the end of this month